OPN5-treated T cells were more cytotoxic toward MEC-1 cells compared with VEH-treated or IBR-treated T cells (Figure 6B), suggesting that BET-i directly enhances CLL patient–derived CD8+ T cell antitumor capacity. The gene discussed is CD8A; the disease is B-cell chronic lymphocytic leukemia.